<DOC>
	<DOC>NCT00787813</DOC>
	<brief_summary>The aim of the study is to evaluate the effect of N-acetyl cysteine (NAC) on pregnancy outcome in women undergoing cervical cerclage for cervical insufficiency.</brief_summary>
	<brief_title>N-Acetyl Cysteine After Cervical Cerclage</brief_title>
	<detailed_description>A randomized controlled clinical trial to be carried out in a university-affiliated tertiary center.Participating women will be randomized into two groups: Group A will be given an oral daily dose of 0.6 g of NAC in effervescent form; group B, serving as controls, will not receive NAC.The two groups will then be compared according to pregnancy outcome.</detailed_description>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>women with history suggestive of cervical insufficiency together with ultrasound findings suggestive of cervical insufficiency undergoing elective cervical cerclage between the 11th and 12th gestational week. singelton viable fetus women tested positive for bacterial vaginosis women currently with threatened abortion (vaginal bleeding or uterinecramps) age older than 35 years or younger than 20 years unwillingness to participate irregular and/or uncertain menstrual dates rupture of membranes previous cesarean delivery possible risks for preterm birth in the current or previous pregnancy such as twin pregnancy, IUFD, malpresentation, known fetal anomaly, progesterone or heparin treatment during the current pregnancy, hypertension, and/or seizure disorders. women with contra indications for cervical cerclage or anesthesia.</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>N-acetyl cysteine (NAC)</keyword>
	<keyword>Cervical cerclage</keyword>
	<keyword>cervical cerclage for cervical insufficiency</keyword>
</DOC>